Tocqueville Asset Management L.P. boosted its position in Novartis AG (NYSE:NVS - Free Report) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118,913 shares of the company's stock after acquiring an additional 11,395 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in Novartis were worth $11,571,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in NVS. Atlanta Consulting Group Advisors LLC bought a new stake in Novartis in the 3rd quarter worth approximately $317,000. Claro Advisors LLC purchased a new position in shares of Novartis during the third quarter worth approximately $533,000. Nixon Peabody Trust Co. lifted its holdings in shares of Novartis by 1.1% in the 3rd quarter. Nixon Peabody Trust Co. now owns 121,770 shares of the company's stock worth $14,006,000 after acquiring an additional 1,294 shares during the last quarter. Fifth Third Wealth Advisors LLC grew its holdings in shares of Novartis by 18.2% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 2,944 shares of the company's stock valued at $339,000 after purchasing an additional 454 shares during the last quarter. Finally, West Family Investments Inc. raised its position in Novartis by 24.7% in the 3rd quarter. West Family Investments Inc. now owns 9,739 shares of the company's stock worth $1,120,000 after purchasing an additional 1,927 shares during the period. Institutional investors own 13.12% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on NVS shares. StockNews.com raised Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. UBS Group restated a "neutral" rating on shares of Novartis in a research report on Thursday, February 13th. Barclays reiterated an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. HSBC cut shares of Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Finally, Morgan Stanley started coverage on shares of Novartis in a report on Wednesday, February 12th. They set an "underweight" rating for the company. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $123.38.
Check Out Our Latest Research Report on NVS
Novartis Trading Down 1.0 %
Shares of Novartis stock traded down $1.10 during midday trading on Friday, reaching $112.11. 3,595,371 shares of the company's stock traded hands, compared to its average volume of 2,240,355. The company has a market cap of $229.15 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The stock has a 50 day moving average of $106.41 and a 200-day moving average of $107.55. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04.
Novartis (NYSE:NVS - Get Free Report) last posted its earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, equities analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.
Novartis Dividend Announcement
The company also recently disclosed a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's payout ratio is 42.69%.
About Novartis
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
